Clinical Trial

Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

Study acronym: ADEPPT
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
ADEPPT is an international, multicentre, single-arm phase II trial. The protocol treatment consists of adagrasib, which is administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.The primary objective of this trial is to assess the clinical efficacy of adagrasib treatment, in terms of objective response, in patients with KRASG12C-mutant NSCLC, including the elderly (≥70 years) or patients with poor performance status (ECOG PS=2).
Protocol Amendment History 2 changes
notable Trial sites reduced: 22 -> 18 locations 2026-06-23
minor Completion pushed: 2026-03 -> 2026-07 2026-04-28
Trial Details
NCT Number NCT05673187
Lead Sponsor ETOP IBCSG Partners Foundation
Collaborators: Mirati Therapeutics Inc.
Conditions NSCLC Stage IV, KRAS P.G12C
Enrollment 68 participants
Start Date 2023-06-12
Primary Completion 2025-07-28 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-22